LATRICE GILLIS: Open Payments
NPI 1891407185 · TONAWANDA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,663 in 76 payments from 15 companies in 2025. Trend: 2023 $93 · 2024 $2,225 · 2025 $1,663
Food & beverage: $1,663
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $283 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $237 |
| ABBVIE INC. | 13 | $224 |
| Vanda Pharmaceuticals Inc. | 7 | $172 |
| Teva Pharmaceuticals USA, Inc. | 12 | $162 |
| Otsuka America Pharmaceutical, Inc. | 6 | $160 |
| Lundbeck LLC | 5 | $121 |
| Janssen Pharmaceuticals, Inc | 3 | $70 |
| Almatica Pharma LLC | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $43 |
Products named: INGREZZA, REXULTI, CAPLYTA, VRAYLAR, FANAPT, AUSTEDO XR, SPRAVATO, LOREEV XR.
Industry payments across NY — which companies pay providers there.
